Thrombin inhibitors are a class of anticoagulant drugs that work by inhibiting thrombin. Thrombin is a serine protease generated in the body during blood coagulation cascade that aids in conversion of fibrinogen to fibrin in order to form blood clots. There has been increased demand for thrombin inhibitor drugs for prevention and treatment of blood clots associated with diseases like deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke.
The global thrombin inhibitor market is estimated to be valued at US$ 30.75 billion in 2023 and is expected to reach US$ 46.85 billion by 2030, growing at a CAGR of 6.2% during the forecast period of 2023-2030
Key Takeaways
Key players operating in the thrombin inhibitor market are Pfizer Inc., Bristol Myers Squibb, Bayer AG, Sanofi S.A., Boehringer Ingelheim GmbH, Johnson and Johnson, Daiichi Sankyo Company, Limited, CSL Behring, Portola Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Novartis International AG, Merck and Co., Inc., Aspen Pharmacare Holdings Limited, Eisai Co., Ltd. Key opportunities in the market include new product approvals, rising prevalence of thrombosis, and increasing demand for anticoagulation therapies in various disease treatments. Advancements in targeted thrombin-inhibiting agents provide improved efficacy and safety over traditional anticoagulants for thrombosis management.
Get More Insights on- Thrombin Inhibitor Market
Market drivers
The rising geriatric population is a key factor fueling growth of the Thrombin Inhibitor Market Demand. Growing prevalence of cardiovascular diseases, increasing demand for novel anticoagulants over warfarin are further driving the market. Other market growth enhancers include new product launches, increasing research on targeted drugs and greater awareness about thrombosis care. Strong pipeline and high potential of novel oral anticoagulants (NOACs) is anticipated to boost adoption of thrombin inhibitors globally over the forecast period.
Get More Insights on- Thrombin Inhibitor Market
For Deeper Insights, Find the Report in the Language that You want:
